Cancer-related Hyponatremia: Enhancing Recognition and Management

Hyponatremia, usually defined by a serum sodium level <135mEq/L, is one of the most common electrolyte disorders associated with tumor-related conditions. Hyponatremia often accompanies, but may sometimes precede, diagnosis of a tumor. The incidence of hyponatremia in patients with cancer can be as high as 47%. Hyponatremia occurs in patients with a variety of solid and hematologic tumors, but more frequently affects patients with small cell lung cancer (SCLC). Despite the frequency of hyponatremia in patients with cancer, it may remain underdiagnosed and undertreated. Uncorrected hyponatremia is associated with diminished response to treatment and poorer outcomes. Correction and stabilization of sodium levels is necessary to undergo chemotherapy and for the beneficial treatment of underlying cancer.This potentially serious condition often presents a challenge to clinicians. This CME activity provides clinicians with strategies and tools for recognition and management of hyponatremia with the goal of improving patient outcomes and survival.

Target Audience

This activity is intended for oncologists, oncology nurses, and other healthcare providers involved in the care of cancer patients with hyponatremia.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  1. Assess and recognize hyponatremia in patients with cancer
  2. Diagnose and manage hyponatremia in patients with cancer
  3. Select the most appropriate therapy for hyponatremia in patients with cancer 



Jorge J. Castillo, MD
Hematologic Malignancies
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, Massachusetts


Joseph G. Verbalis, MD
Professor of Medicine
Chief, Endocrinology and Metabolism
Georgetown Director
Georgetown-Howard Universities Center for Clinical and Translational Science
Georgetown University


Christian Grohé, MD
Professor of Medicine
Chief, Department of Respiratory Diseases
ELK Thorax Center
Berlin, Germany



Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflict of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Relationship Identified With:

Jorge J. Castillo, MD

Consultant/Advisor: Otsuka America Pharmaceutical, Inc.

Joseph G. Verbalis, MD

Consultant/Advisor: Ferring Pharmaceuticals; Otsuka America Pharmaceutical, Inc.

Research Grant: Otsuka America Pharmaceutical, Inc.

Christian Grohé

Has disclosed no relevant financial relationships.


Non-Faculty: Bernard M. Abrams, MD, Sandy Breslow, Brynne Hunter, Rob Lowney, Dana Ravyn, PhD, MPH, and Rachael Soranno, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This CME/CE activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and CMEology. 


Course Open Date: September 29, 2015 | Course Expiration Date: September 28, 2016

CME Credit (Physicians)

This activity has been planned and implemented with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Elsevier Office of Continuing Medical Education and CMEology. Elsevier Office of CME is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses)

Dannemiller is accredited by the California Board of Registered Nursing (CBRN), Provider Number 4229. This activity has been approved for 1.0 contact hour. CBRN is not accepted by Michigan and Utah State licensing boards.

AANP Credit (Nurse Practitioners)

cid:image001.jpg@01D143B8.014EA5F0 Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education . Provider Number 090419. This program was is accredited for 1.0 contact hour. 

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; CMEology and Otsuka America Pharmaceutical, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.